A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia
- 15 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (6), 1744-1755
- https://doi.org/10.1158/1078-0432.ccr-20-4576
Abstract
Purpose: Although considerable progress has been made with autologous T cell-based therapy in B cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity that is of particular concern in the elderly CLL population. Vγ9Vδ2-T cells form a conserved T cell subset with strong intrinsic immunotherapeutic potential, largely because of their capacity to be triggered by phosphoantigens that are overproduced by CLL and many other malignant cells. Specific activation of Vγ9Vδ2-T cells by a bispecific antibody may therefore improve the efficacy and toxicity of autologous T cell-based therapy in CLL. Experimental Design: We evaluated CD1d expression in a cohort of 78 untreated CLL patients and generated a CD1d-specific Vγ9Vδ2-T cell engager based on single-domain antibodies (VHHs). Results: We identified CD1d as a suitable target for antibody-based therapy in the majority of CLL patients, particularly in patients with advanced disease. The CD1d-specific Vγ9Vδ2-T cell engager induces robust activation and degranulation of Vγ9Vδ2-T cells, enabling Vγ9Vδ2-T cells from CLL patients to lyse autologous leukemic cells at low effector to target ratios. The expression of CD1d on CLL cells is upregulated by all-trans retinoic acid, and sensitizes the malignant cells to bispecific VHH-induced lysis. Furthermore, we provide evidence that the Vγ9Vδ2-T cell receptor retains its responsiveness to phosphoantigens when the bispecific VHH is bound, and aminobisphosphonates can therefore enhance bispecific Vγ9Vδ2-T cell engager-mediated tumor-specific killing. Conclusion: Collectively, our data demonstrate the immunotherapeutic potential of this novel CD1d-specific Vγ9Vδ2-T cell engager in CLL.Funding Information
- VU (000483)
- Worldwide Cancer Research (140343)
This publication has 64 references indexed in Scilit:
- Six-of-the-best: unique contributions of γδ T cells to immunologyNature Reviews Immunology, 2013
- Invariant natural killer T cells: an innate activation scheme linked to diverse effector functionsNature Reviews Immunology, 2013
- Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapyHaematologica, 2012
- Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cellsHaematologica, 2011
- Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humansClinical Immunology, 2011
- CD1d and CD1c Expression in Human B Cells Is Regulated by Activation and Retinoic Acid Receptor SignalingThe Journal of Immunology, 2011
- Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphomaAmerican Journal of Hematology, 2010
- In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patientsClinical and Experimental Immunology, 2010
- Regulation of multiple myeloma survival and progression by CD1dBlood, 2009
- γδ T cells for immune therapy of patients with lymphoid malignanciesBlood, 2003